MyAlcon Professionals Logo
MyAlcon for Consumer

My Alcon | Language

This page is available in English. Select below for other countries.

Select another country

See the powerful efficacy of ROCKLATAN®

(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% 

Once-daily ROCKLATAN® delivered
superior efficacy1

Up to 2.6 mmHg additional IOP reduction compared to latanoprost alone graphic
Up to 2.6 mmHg additional IOP reduction compared to latanoprost alone graphic

Study Designs

 

ROCKLATAN® was evaluated in 2 randomized, controlled clinical trials in patients with open-angle glaucoma and ocular hypertension, with baseline IOP <36 mmHg. These studies compared the IOP-lowering effect of ROCKLATAN® dosed once daily to individually administered netarsudil 0.02% once daily and latanoprost 0.005% once daily. The treatment durations for these studies were 12 months for MERCURY-1 and 3 months for MERCURY-2. The average IOP-lowering effect of ROCKLATAN® was 1 to 3 mmHg greater than monotherapy with either netarsudil 0.02% or latanoprost 0.005% throughout 12 months in MERCURY-1 and 3 months in MERCURY-2.2

Up to 9 mmHg reduction from baseline in mean diurnal IOP at Week 2
Up to 9 mmHg reduction from baseline in mean diurnal IOP at Week 2
Up to 36% reduction from baseline in mean diurnal IOP at Week 2
Up to 36% reduction from baseline in mean diurnal IOP at Week 2

For patients like Gary, consider ROCKLATAN® for powerful IOP reduction

PATIENT DETAILS*

• 67 years old

• Open-angle glaucoma with elevated IOP

• No comorbidities

PATIENT STATUS

• Gary has received selective laser trabeculoplasty in the past year and is currently taking latanoprost. He has reduced his IOP from 25 mmHg to 21 mmHg, but his ophthalmologist would like to aim for a target IOP of 19 mmHg

• He is concerned about adding another bottle to his regimen

 

TREATMENT PLAN

 

Consider replacing latanoprost with ROCKLATAN® for additional IOP lowering

*Hypothetical patient.

IOP=Intraocular pressure;


mmHg=Millimeters of mercury.

 

REFERENCES    
 

1. Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020;3(5):327-338.

2. Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information. Aerie Pharmaceuticals, Inc., Irvine, CA. 2020.

3. Alcon data on file, 2022.

 

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Epithelial corneal edema, described as honeycomb or bullous, has been reported in some patients with pre-existing corneal stromal edema or following ocular procedures that could affect corneal endothelial function. Epithelial corneal edema typically resolves upon discontinuation of ROCKLATAN®. Advise patients to notify their physician if they experience eye pain or decreased vision while using ROCKLATAN®.

INDICATIONS AND USAGE

 

ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  • Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.
  • Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.
  • Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.
  • Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
  • Contact lenses should be removed prior to the administration of ROCKLATAN® and may be reinserted 15 minutes after administration.

 

INDICATIONS AND USAGE

 

ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

 

Adverse Reactions

 

The most common ocular adverse reaction observed in controlled clinical studies with ROCKLATAN® was conjunctival hyperemia which was reported in 59% of patients. Five percent of patients discontinued therapy due to conjunctival hyperemia. Other common ocular adverse reactions reported were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

 

Please click here for the ROCKLATAN® Full Prescribing Information.

©2025 Alcon Inc. 3/25 US-ROC-2500009